Allergic conjunctivitis secondary prevention: Difference between revisions
| Line 8: | Line 8: | ||
====[[Pharmacological]] measures<ref name="pmid31993069">{{cite journal| author=Dupuis P, Prokopich CL, Hynes A, Kim H| title=A contemporary look at allergic conjunctivitis. | journal=Allergy Asthma Clin Immunol | year= 2020 | volume= 16 | issue= | pages= 5 | pmid=31993069 | doi=10.1186/s13223-020-0403-9 | pmc=6975089 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31993069 }} </ref>==== | ====[[Pharmacological]] measures<ref name="pmid31993069">{{cite journal| author=Dupuis P, Prokopich CL, Hynes A, Kim H| title=A contemporary look at allergic conjunctivitis. | journal=Allergy Asthma Clin Immunol | year= 2020 | volume= 16 | issue= | pages= 5 | pmid=31993069 | doi=10.1186/s13223-020-0403-9 | pmc=6975089 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31993069 }} </ref>==== | ||
The dual-activity agents are considered first-line. When [[symptoms]] and [[signs]] remain uncontrolled, a short course of [[topical]] [[ophthalmic]] [[steroids]] may be considered which might need monitoring by an [[eye]] care specialist is necessary if prescribed for longer term. Other treatments include concomitant use of [[nasal]] [[steroids]], [[oral]] [[anti-histamines]] and/or [[topical]] [[ophthalmic]] [[NSAIDs]]. [[Immunotherapy]], either [[subcutaneous]] or [[sublingual]], can be considered when [[medical]] [[therapy]] is insufficient, poorly tolerated or for patient preference. | The dual-activity agents are considered first-line. When [[symptoms]] and [[signs]] remain uncontrolled, a short course of [[topical]] [[ophthalmic]] [[steroids]] may be considered which might need monitoring by an [[eye]] care specialist is necessary if prescribed for longer term. Other treatments include concomitant use of [[nasal]] [[steroids]], [[oral]] [[anti-histamines]] and/or [[topical]] [[ophthalmic]] [[NSAIDs]]. [[Immunotherapy]], either [[subcutaneous]] or [[sublingual]], can be considered when [[medical]] [[therapy]] is insufficient, poorly tolerated or for patient preference. | ||
====[[Non-pharmacological]] measures==== | |||
==References== | ==References== | ||
Revision as of 04:19, 30 August 2022
|
Allergic conjunctivitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Allergic conjunctivitis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Allergic conjunctivitis secondary prevention |
|
Risk calculators and risk factors for Allergic conjunctivitis secondary prevention |
Overview
Secondary Prevention
Early diagnosis
The diagnosis should be confirmed and the severity assessed by a proper history and a thorough physical examination.
Treatment
Pharmacological measures[1]
The dual-activity agents are considered first-line. When symptoms and signs remain uncontrolled, a short course of topical ophthalmic steroids may be considered which might need monitoring by an eye care specialist is necessary if prescribed for longer term. Other treatments include concomitant use of nasal steroids, oral anti-histamines and/or topical ophthalmic NSAIDs. Immunotherapy, either subcutaneous or sublingual, can be considered when medical therapy is insufficient, poorly tolerated or for patient preference.
Non-pharmacological measures
References
- ↑ Dupuis P, Prokopich CL, Hynes A, Kim H (2020). "A contemporary look at allergic conjunctivitis". Allergy Asthma Clin Immunol. 16: 5. doi:10.1186/s13223-020-0403-9. PMC 6975089 Check
|pmc=value (help). PMID 31993069.